JP2023531493A5 - - Google Patents

Info

Publication number
JP2023531493A5
JP2023531493A5 JP2022578995A JP2022578995A JP2023531493A5 JP 2023531493 A5 JP2023531493 A5 JP 2023531493A5 JP 2022578995 A JP2022578995 A JP 2022578995A JP 2022578995 A JP2022578995 A JP 2022578995A JP 2023531493 A5 JP2023531493 A5 JP 2023531493A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
variable domain
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022578995A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023531493A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/039191 external-priority patent/WO2021263167A2/en
Publication of JP2023531493A publication Critical patent/JP2023531493A/ja
Publication of JP2023531493A5 publication Critical patent/JP2023531493A5/ja
Priority to JP2026069044A priority Critical patent/JP2026123093A/ja
Withdrawn legal-status Critical Current

Links

JP2022578995A 2020-06-26 2021-06-25 Il-10突然変異タンパク質及びその融合タンパク質 Withdrawn JP2023531493A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026069044A JP2026123093A (ja) 2020-06-26 2026-04-17 Il-10突然変異タンパク質及びその融合タンパク質

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063045041P 2020-06-26 2020-06-26
US63/045,041 2020-06-26
US202063199218P 2020-12-14 2020-12-14
US63/199,218 2020-12-14
PCT/US2021/039191 WO2021263167A2 (en) 2020-06-26 2021-06-25 Il-10 muteins and fusion proteins thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026069044A Division JP2026123093A (ja) 2020-06-26 2026-04-17 Il-10突然変異タンパク質及びその融合タンパク質

Publications (2)

Publication Number Publication Date
JP2023531493A JP2023531493A (ja) 2023-07-24
JP2023531493A5 true JP2023531493A5 (cg-RX-API-DMAC7.html) 2024-06-19

Family

ID=77071744

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022578995A Withdrawn JP2023531493A (ja) 2020-06-26 2021-06-25 Il-10突然変異タンパク質及びその融合タンパク質
JP2026069044A Pending JP2026123093A (ja) 2020-06-26 2026-04-17 Il-10突然変異タンパク質及びその融合タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026069044A Pending JP2026123093A (ja) 2020-06-26 2026-04-17 Il-10突然変異タンパク質及びその融合タンパク質

Country Status (17)

Country Link
US (1) US12630598B2 (cg-RX-API-DMAC7.html)
EP (1) EP4172184A2 (cg-RX-API-DMAC7.html)
JP (2) JP2023531493A (cg-RX-API-DMAC7.html)
KR (1) KR20230027300A (cg-RX-API-DMAC7.html)
CN (1) CN116209459A (cg-RX-API-DMAC7.html)
AU (1) AU2021296917A1 (cg-RX-API-DMAC7.html)
CA (1) CA3187576A1 (cg-RX-API-DMAC7.html)
CL (3) CL2022003755A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023000431A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230025A (cg-RX-API-DMAC7.html)
IL (2) IL330191A (cg-RX-API-DMAC7.html)
JO (1) JOP20220348A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022016548A (cg-RX-API-DMAC7.html)
PE (1) PE20231082A1 (cg-RX-API-DMAC7.html)
TW (1) TW202216743A (cg-RX-API-DMAC7.html)
UY (1) UY39298A (cg-RX-API-DMAC7.html)
WO (1) WO2021263167A2 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024131600A1 (zh) * 2022-12-24 2024-06-27 广东菲鹏制药股份有限公司 Il10突变体、融合蛋白和药物
CN116425857B (zh) * 2023-06-09 2023-08-18 苏州依科赛生物科技股份有限公司 一种无糖基化修饰的il-15及制备方法
CN117143235B (zh) * 2023-10-26 2024-02-09 中国科学院苏州纳米技术与纳米仿生研究所 一种单克隆抗体及应用
CN121108363A (zh) * 2024-06-12 2025-12-12 广东菲鹏制药股份有限公司 一种融合蛋白及其用途

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
DE19851675A1 (de) 1998-11-10 2000-05-11 Bayer Ag Menschliche Interleukin-10 Mutantenproteine
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
AU2001231532A1 (en) 2000-02-11 2001-08-20 Maxygen Aps Improved interleukin 10
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
WO2004044006A1 (en) * 2002-11-14 2004-05-27 Maxygen, Inc. Conjugates of interleukin-10 and polymers
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
DE602006011311D1 (de) 2005-05-31 2010-02-04 Univ Colorado Il-10 mutante
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
AU2009290544B2 (en) 2008-09-12 2015-07-16 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
KR101050829B1 (ko) 2008-10-02 2011-07-20 서울대학교산학협력단 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 항암제
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
JP6411218B2 (ja) 2012-02-15 2018-10-24 ノヴォ ノルディスク アー/エス 骨髄細胞で発現されるトリガー受容体1(trem−1)に結合し、それを遮断する抗体
US9346872B2 (en) 2012-08-08 2016-05-24 Roche Glycart Ag Interleukin-10 fusion proteins
MX385794B (es) 2012-09-07 2025-03-18 Inst Nat Sante Rech Med Péptidos inhibidores obtenidos del receptor desencadenante expresado en células mieloides de tipo 1 (trem-1) y transcrito similar a trem 1 (tlt-1) y usos de los mismos.
JP2016526014A (ja) * 2013-04-24 2016-09-01 アルモ・バイオサイエンシーズ・インコーポレイテッド インターロイキン−10組成物及びその使用
SI3021873T1 (sl) * 2013-07-18 2018-12-31 Xalud Therapeutics, Inc. Sestavek za zdravljenje vnetne sklepne bolezni
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
BR112016016658A2 (pt) 2014-02-06 2018-01-23 F. Hoffmann-La Roche Ag proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão
CN106536559B (zh) 2014-07-17 2021-04-27 诺和诺德股份有限公司 定点诱变trem-1抗体以降低黏度
US10144768B2 (en) 2015-12-04 2018-12-04 Novartis Ag Antibody cytokine engrafted compositions and methods of use for immunoregulation
JP7023853B2 (ja) 2016-03-04 2022-02-22 アレクトル エルエルシー 抗trem1抗体及びその使用方法
MX2020007291A (es) 2018-01-12 2020-09-10 Amgen Inc Anticuerpos anti-pd-1 y metodos de tratamiento.
CR20250022A (es) 2018-04-02 2025-02-25 Bristol Myers Squibb Co Anticuerpos anti-trem-1, ácidos nucleicos y vectores de los mismos (divisional 2020-0450)
JP2022512746A (ja) 2018-10-19 2022-02-07 アンブルックス,インコーポレイテッド インターロイキン-10ポリペプチド複合体、その二量体、およびそれらの使用

Similar Documents

Publication Publication Date Title
JP2024038040A5 (cg-RX-API-DMAC7.html)
EP3072905B1 (en) Il-17a binding agent and uses thereof
JP2023505492A5 (cg-RX-API-DMAC7.html)
CN103154029B (zh) 抗人tweak的抗体及其用途
RU2007129676A (ru) Антитела к рецептору альфа 1 il-13 и их применение
RU2011101969A (ru) Антитела к человеческому интерлейкину-20
CN106459216A (zh) 多特异性抗体构建体
JP2019522961A5 (cg-RX-API-DMAC7.html)
JP2020505386A5 (cg-RX-API-DMAC7.html)
TW201917135A (zh) 抗TNF/抗IL-23 IgG雙特異性抗體
JP2007530435A5 (cg-RX-API-DMAC7.html)
JP2016511277A5 (cg-RX-API-DMAC7.html)
RU2008129787A (ru) Фармацевтические композиции с устойчивостью к растворимому сеа
CN101679516A (zh) 靶向金黄色葡萄球菌ORF0657n的抗原结合蛋白
CN108473568A (zh) 对TNF-α、IL-17A和IL-17F具有特异性的多特异性抗体分子
EP3464349A2 (en) Compositions and methods for antibodies targeting staphylococcal leukotoxins
JP6949012B2 (ja) B型肝炎表面抗原に対する抗体及びその使用
JPWO2012026309A1 (ja) 抗pad4抗体医薬の創成
JP2022513043A5 (cg-RX-API-DMAC7.html)
JP2023553694A5 (cg-RX-API-DMAC7.html)
JP2018525032A5 (cg-RX-API-DMAC7.html)
WO2020090892A1 (ja) 抗ヒトFn14抗体
JP2021530511A5 (cg-RX-API-DMAC7.html)
JP6678661B2 (ja) 新規ポリペプチド
US10793643B2 (en) PCSK9 antibody, antigen-binding fragment thereof, and medical application thereof